We’ve seen The Scout™ on these pages almost a year ago. This device for screening type 2 diabetes from VeraLight, Inc., of Albuquerque, New Mexico, was just presented at the ongoing 67th annual meeting of the American Diabetes Association held in Chicago. Now the company seems to have the newer, spiffier version of the device, with the same proprietary fluorescence spectroscopic technology that detects advanced glycation endproducts (AGEs).
According to the firm::
Previously reported studies of a prototype of the portable desktop system have shown it outperforms both the fasting plasma glucose (FPG) test and the A1C test as a rapid and non-invasive screen for pre-diabetes and type 2 diabetes. The investigational device, not yet approved for use in the United States, is being designed for use at physician-supervised point-of-care locations…
Analogous to a “diabetes odometer,” AGEs are a sensitive metric for the cumulative damage the body endures due to the effects of abnormally high blood sugar and oxidative stress. AGEs harm the proteins that make up the blood vessels, connective tissue, and are thought to be major factors in aging and age-related chronic diseases. According to medical experts, non-invasive skin detection of AGEs could replace the FPG test as the medical workhorse for screening people suspected of having diabetes.